ÂÜÀòÂÒÂ×

Michael Serrano-Wu has been a key driver for several first-in-class drug discovery efforts. At BMS, he catalyzed the nascent field of HCV NS5A-based therapy by designing the first known palindromic inhibitor, leading to the discovery of daclatasvir and an entire class of follow-on drugs. Later at Novartis, Mike led the team which discovered pradigastat, a DGAT1 inhibitor currently in clinical investigation. More recently, Mike has been instrumental in the inception, development and partnering of two cardiovascular therapeutic assets; a small molecule inhibitor of PCSK9 partnered to AstraZeneca and an inhibitor of ApoL1.